Duane Morris LLP
Cancer therapy with a parvovirus combined with a BCL-2 inhibitor
Described is a pharmaceutical composition comprising (a) a parvovirus and (b) an Bcl-2 inhibitor and the use of said composition for treatment of cancer, e.g., a solid tumor. Preferred inhibitors are the BH3 mimetics ABT-737 and ABT-199.
DEUTSCHES KREBSFORSCHUNGSZENTRUM RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG
A A A A C A A A A
A61K A61P A61K A61K C12N A61K A61P A61K A61K
inventional inventional inventional inventional additional inventional inventional inventional inventional
Jean Junwei Karsten Antonio Lea
Rommelaere Li Geletneky Marchini Schroeder